Topics

FDA Accepts Merck’s sBLAs for Keytruda Six-Week Dosing Schedule for Melanoma and Multiple Other Indications

11:16 EDT 10 Jul 2019 | Speciality Pharma Journal

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review six supplemental Biologics License Applications (sBLAs) to update the dosing frequency for KEYTRUDA, Merck’s anti-PD-1 therapy, to include an every-six-weeks (Q6W) dosing schedule option. Merck is seeking …

Original Article: FDA Accepts Merck’s sBLAs for Keytruda Six-Week Dosing Schedule for Melanoma and Multiple Other Indications

NEXT ARTICLE

More From BioPortfolio on "FDA Accepts Merck’s sBLAs for Keytruda Six-Week Dosing Schedule for Melanoma and Multiple Other Indications"

Quick Search

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...